Chris Boerner is the Vice President of Marketing at Seattle Genetics.

He spent a number of years previously at Genentech specialising in marketing Oncology products.

Prior to this, Chris has also worked for Mckinsey & Co and Accenture.

Chris received his P.H.D from Berkeley in Business & Economics and also holds an A.B in Economics and History from Washington University in St. Louis.

Dr. Michael Sherman is the chief medical officer and senior vice president of Harvard Pilgrim Health Care, a not-for-profit health plan that has been ranked the #1 private health plan in America for the past eight years according to an annual ranking of the nation's best health plans by the National Committee for Quality Assurance (NCQA). In this role, he is responsible for Harvard Pilgrim's clinical departments, provider engagement strategy, health promotion initiatives, outreach and disease management services, pharmacy services, NCQA accreditation and quality and utilization programs. As Harvard Pilgrim's chief physician, he works externally with physicians and health care organizations in the region and across the nation to achieve sustainable improvements in cost and quality.

Prior to joining Humana, Dr. Sherman held several leadership positions with Humana, UnitedHealth Group, and Thomson Medstat (now Thomson Reuters). He holds a B.A. in Anthropology and Natural Sciences and an M.S. in Biomedical Anthropology from the University of Pennsylvania and received his M.D. from Yale and an M.B.A. from the Harvard Business School. Dr. Sherman is a diplomate of the American Board of Anesthesiology and American Board of Medical Management, and was named a fellow of the American College of Physician Executives in recognition of his national contributions to the field of medical management.

Ms. Housman is responsible for worldwide market access and pricing for Novartis Molecular Diagnostics, a business unit within Novartis Pharma AG. Previously, Ms. Housman was Executive Director of Marketing for Charles River Laboratories, focused on worldwide Preclinical, First in Human and Biopharmaceutical Services. Prior to Charles River, Ms. Housman led marketing and commercialization strategies in support of managed care outreach as Director of Marketing for Genzyme Genetics, a business unit of Genzyme Corporation. In addition to her work within industry, Ms. Housman spent a decade leading health services evaluation, contracting, and provider profiling initiatives as a Director within BlueCross BlueShield of Massachusetts. Ms. Housman holds a Master of Business Administration with honors from Boston University Graduate School of Management, a Master of Public Health with specialization in Health Services from Boston University School of Public Health, and a Bachelor of Arts degree in Economics with a minor in Business Administration from Boston University College of Arts and Sciences.

Ms. Housman is based in Massachusetts as part of the Novartis Molecular Diagnostics Cambridge office.

Raechele M. McMahan is the Head of Clinical Strategy for Aetna Pharmacy. Raechele is responsible for Clinical Program and Utilization Management Development, Formulary Strategy, Specialty Manufacturer Contracting, and developing relationships with pharmaceutical companies and retail pharmacies to support strategic goals across Aetna. Previously Raechele has held positions with Aetna Specialty Pharmacy including Head of Data Reporting and Analytics and Clinical Development. Raechele's innovative programs attributed to millions in savings to the health plan for Medical Pharmacy drugs paid under the Medical and Pharmacy benefit.

Ms. McMahan has more than 10 years of experience in healthcare, including a previous tenure with Health Net, Incorporated. During that time she was a senior member in the Risk Management department and managed preparing and ensuring compliance with the Sarbanes-Oxley Act in the areas of National Provider Networks, Group Contracting, Broker Compensation and Treasury risk. She also played a prominent role in preparing the executive team for the quarterly earnings call. Prior to that she worked for Orlando Health where she was in charge of Administration Management for Cardiac Services and oversaw financial, information technology and contract development.

She has a Bachelors of Science degree in Health Services Administration from the University of Central Florida and a Masters of Business Administration with a focus in Health Care from the University of Phoenix. While attending University of Central Florida she was provided an internship with Adventist Health Systems and Orlando Health.

Anthony acts as the industry liaison coupling the manufactures needs with effective strategies that pharmacies can implement. Building on ten years of strategy and contract development he works with manufacturer partners to deliver "First to Market" programs intended to maximize patient outcomes.

Before joining Armada, Anthony worked for Roche Laboratories holding roles in Finance, Strategic Pricing and Trade Relations. As a Manager in the Trade Segment of Customer Planning & Contracting, Anthony was responsible for the contracting continuum within the Specialty Pharmacy and Specialty Distributor market segments. This included Business Planning, Strategy & Tactical planning and Contract Development for new and in line products. Additionally he had oversight of day to day contracting activities as well as forecasting & reporting. Prior to that Anthony held the position of Economic Analysis Manager in the Strategic Pricing & Contracting Group where he worked on new and inline product pricing as well as GPO, Hospital, Clinic and MCO/PBM contracting strategies.

He has dual degrees in Economics and Italian from Rutgers College.

Dr. Turnham is Executive Director of the Melanoma Research Foundation, the largest and oldest independent non-profit focusing on melanoma. Turnham joined the MRF in January 2009 and his responsibilities include oversight of the Foundation's research, education and advocacy work.

Turnham's efforts have led to the establishment and expansion of several initiatives to serve the melanoma community, including patient support programs, a national volunteer initiative and strategic partnerships with stakeholders. Under his leadership, the MRF has promoted better access to cutting-edge treatments for patients with advanced melanoma, spotlighted the issue of tanning for lawmakers and regulators, and facilitated collaborative research efforts to advance combination trials through the MRF's Melanoma Breakthrough Consortium.

With a strong background in patient advocacy and non-profit development, Turnham has brings to the MRF and the melanoma community more than 30 years of experience in management, fundraising, communication, teaching and research.

Prior to joining the MRF, Turnham served as the chief executive officer for the Colon Cancer Alliance (CCA). His work at the CCA led to the creation of a new marketing initiative and a series of grassroots fundraising events that remain the organization's largest source of revenue. His work at the CCA also led to new organization branding, enhanced digital presences and a revised chapter program to expand reach and increase revenue generation.

Turnham previously served as Director of Development for the United Cerebral Palsy Associations, the Whitman-Walker Clinic, as well as the Children's Research Institute at the Children's National Medical Center.

Turnham holds a B.A. in microbiology from the University of Tennessee and worked in medical research laboratories for seven years while earning a Master of Divinity from the New Orleans Baptist Theological Seminary and a Ph.D. in ethics from the Southern Baptist Theological Seminary. He was a full-time Baptist pastor for twelve years before moving into the non-profit health sector. Throughout his career he has taught in higher education, most recently serving as adjunct professor in the University of Maryland's Honors Program.

Dr. Ira Klein is an AOA graduate of UMDNJ/RWJMS, with residency training at Brown University and UMDNJ/RWJMS, completed in 1994, active board certification in Internal Medicine, and an MBA from Rutgers in 2000. Dr. Klein has been with Aetna since April of 2006, and, as of September 2011, is the Chief of Staff to the Chief Medical Officer, responsible for communicating and deploying the strategic efforts of the CMO in multiple areas, including leveraging of business acquisitions, and clinician and clinical program development. Before that, he operated for two years in the National Accounts Sales and Support group at the corporate level, involved in the development of new benefits designs, financial and clinical analytics for National Accounts, and the evolution of oncology strategies. His previous responsibilities were as a Medical Director in the Northeast Region for four years at Aetna. Prior to that, Dr. Klein was the Medical Director for Quality and Case Management at Bayshore Community Health Services, overseeing UM and CM activities, as well as PRO, Medicaid, and CMS relationships. He was also the Chief Medical Officer of Elderplan, an 11,000 member Medicare Social HMO focusing on the frail elderly, from 2001-2003. Previously, he began teaching and practicing internal medicine as Assistant Professor of Medicine at UMDNJ/RWJMS, acting as the Medical Director of a Skilled Nursing Facility for five years along with Hospitalist, office practice, and administrative responsibilities. His professional affiliations include: ACP, AHIP, and AOA, and currently is a Clinical Assistant Professor of Medicine at UMDNJ/RWJMS.

Dr. Beckie Fenrick is responsible for the oversight and development of Blue Cross Blue Shield of Florida's clinical pharmacy programs, medical pharmacy operations, and specialty pharmacy management. Dr. Fenrick's extensive professional experience with product launches, rebate negotiations, formulary development, pharmacy operations, and vendor oversight is an asset to her role. In addition, she manages all clinical pharmacy program development and is a representative of the Pharmacy & Therapeutics Committee, Medical Policy Coverage Committee and chairperson of the Pharmacy Policy Committee.

Prior to joining Blue Cross Blue Shield of Florida in 2007, Fenrick was Vice President of Clinical Services at Innoviant, a Wisconsin-based PBM. She has over 25 years of experience as a clinical pharmacist specializing in pharmacy benefits administration.

A native of Janesville, WI, Dr. Fenrick earned her Bachelor of Science in Pharmacy degree from the University of Wisconsin-Madison, Master of Business Administration degree from the University of Wisconsin-Whitewater, and Doctor of Pharmacy degree from the University of Florida. She is a member of the Academy of Managed Care Pharmacy serving on the Educational Affairs Committee, and a member of the International Society for Pharmacoeconomic Outcomes Research.

Dr. Fenrick resides in Florida.

Debbie Warner is Vice President, Oncology Market Access for Kantar Health. In that role she leads a team of experts in Oncology Market Access who are responsible for the production of the syndicated reports, "Oncology Market Access U.S" She also oversees custom consulting engagements related to oncology market access issues for biopharmaceutical products and is a domain expert to internal and external clients. Debbie has 20+ years of experience within the pharmaceutical industry with Merck, Astra Merck and most recently AstraZeneca. Debbie has held positions in field sales, national accounts, brand management, medical affairs and managed markets strategy. Prior to joining Kantar Health, Debbie was the Managed Markets Brand Director, Specialty Care Oncology Growth Brands, where she leveraged her commercial and clinical experience and payer perspectives to launch and grow brands with broad market access.

Coming Soon...

Richard Boyajian is currently the Clinical Director of the Adult Survivorship Program at Dana-Farber Cancer Institute where he has worked since early 2002.

Prior to this Richard gained a medical education at the University of Massachusetts Medical School.

Andrea joined Bristol-Myers Squibb (BMS) as an Associate Director, Customer Analytics during July, 2011. Ms. Adams provides expertise in Business Analytics and Management Science for the World Wide Market Research and Business Intelligence group within BMS. She is currently working on building a "best in class" analytics environment for the WWMRBI department, improving analytics capabilities through standardization and implementing best practices.

Andrea's career has centered around healthcare and pharmaceuticals analytics and reporting. She has served as a strategic business partner to various companies including: Eisai, Merck, Bracco Diagnostics, SDI Health, IMS Health, Aetna, Highmark and Independence Blue Cross.

Andrea holds a bachelor's degree from Ball State University, a MPA from Rutgers University and a MS in Information Science from Pennsylvania State University.

Joshua Rademacher is currently the Vice President of Strategic Market Initiatives at Oncology Plus Inc.

Josh began his career as an analyst for Lazard Middle Market and has since had high involvement in a number of successful enterprise ventures.

He was educated at Marquette University, where he gained a Bsc in Applied Economics, Finance and Political Philosophy.

Coming Soon...

Coming Soon...

Coming Soon...

Darshan Wariabharaj is currently Director, Drug Regulatory Affairs (DRA), Novartis Oncology. Darshan is responsible for strategic and operational regulatory direction through development, registration and approval/post-approval. By ensuring the execution of regulatory plans in line with global regulatory strategy in close collaboration with the local and global project teams. Since 1994, as a global regulatory affairs professional, Darshan's development of (in conjunction with other line functions, Country Pharma Organizations, key opinion leaders) regulatory plans and their execution has resulted in the successful development and approval of pharmaceutical products in a variety of therapeutic areas. Since 2001, Darshan's focus has been market access in Oncology. In 2011, Darshan was a recipient of the Novartis Oncology President's Award - Special Regulatory Approval (Key Contributor): US, EU and Japan and a recipient the Novartis Oncology US Business Excellence Award 2010 - Competitiveness - Launch Team. Before joining Novartis Oncology, Darshan held DRA positions at Eisai Medical Research, OSI Pharmaceuticals, Novartis Pharmaceuticals Canada Inc., Inveresk Research International and Mallinckrodt Veterinary. Before joining the Pharmaceutical Industry, Darshan was a research assistance at the University of St.Andrews in Scotland. Darshan received his Bachelors of Science Degree (with Honors) from the University of Plymouth.

Coming Soon...

Rebecca Shanahan is currently a Board Member of Oncology Plus Inc. She has extensive experience in specialty was formerly the President of Specialty Services and the Executive Vice President at Aetna Specialty Pharmacy.

Rebecca finished her education at Indiana University School of Law - Bloomington.

Jason Carlin is a Deputy Director of Management Science at Bayer Healthcare in Wayne, New Jersey. He has experience across a wide range of sales and marketing topics and delivers comprehensive, integrated solutions to business partners to support business decisions and investment choices.

His specialties include: Mining actionable insights to support data-driven decisions, predictive analytics, sales force design (size/structure and alignment), segmentation, resource allocation, targeting / call planning, personnel placement, incentive compensation, promotion response, ROI, sample optimization, marketing mix models, expediting patient enrollment for clinical trials and launch products.

He is a board member of PMSA (Pharmaceutical Management Science Association) which is not-for-profit organization promoting the advancement of Management Science in the pharmaceutical industry.

Previously, he worked for Eisai Pharmaceuticals, ZS Associates, Harrah's Entertainment and Lockheed Martin.

Jason received a Master's of Industrial and Systems Engineering from Cornell University, and a B.S. in Industrial & Systems Engineering from the University of Florida.

Coming Soon...

Mr. White has over a decade of experience in the pharmaceutical industries, with a focus in specialty and biotech. Mr. White provides strategic guidance to clients in market access, coverage and reimbursement, launch planning, patient program design, pricing, and contracting. He has extensive understanding of various aspects of healthcare reform and the impact to the pharmaceutical industry, having worked with Washington insiders for the past four years. Prior to joining inVentiv Health in 2010, he held various leadership roles in consulting, program management, and business development at PAREXEL Consulting, HealthBridge, and CuraScript. Mr. White holds a BS Business from Post University and is a Certified Professional Coder with the American Academy of Professional Coders.

Coming Soon...

Mr. Mathews has worked on a variety of reimbursement projects identifying public and private payer coverage channels, coding options, and pricing and payment possibilities for drugs, diagnostics, and medical devices. His specific area of expertise is in diagnostics with a focus on value-based pricing for laboratory tests and molecular diagnostics. His experience includes work with both test and platform developers and laboratories, drug/diagnostic combinations, and pharmaceutical product launches. Mr. Mathews’ prior experience includes working on health policy as a legislative aide on Capitol Hill. He has also worked for the government affairs office of Genentech and has participated in a National Institutes of Health sponsored clinical trial which focused on genetic testing for Alzheimer’s disease. Mr. Mathews has a master’s degree in public policy from Duke University and completed his undergraduate work at Colgate University